Harbin Medisan Pharmaceutical Co., Ltd. (SHE:002900)

Market Cap	3.70B +23.8%
Revenue (ttm)	874.60M -20.7%
Net Income	-190.75M
EPS	-0.61
Shares Out	309.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.20 (1.69%)
Ex-Dividend Date	May 29, 2025

Volume	2,958,110
Average Volume	5,544,831
Open	11.75
Previous Close	11.95
Day's Range	11.75 - 12.13
52-Week Range	9.40 - 18.18
Beta	0.54
RSI	37.96
Earnings Date	Apr 28, 2026

About SHE:002900

Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium folinate for injection, hydroxylcamptothecine injection, tropisetron hydrochloride for injection, tropisetron hydrochloride and glucose injection, gabexate...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 2,522
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002900

Financial Performance

In 2024, SHE:002900's revenue was 1.13 billion, a decrease of -4.58% compared to the previous year's 1.19 billion. Earnings were 58.68 million, a decrease of -20.35%.